MAETZOLD DEREK J 4

What Happened
Derek J. Maetzold, President & CEO and a director of Castle Biosciences (CSTL), exercised stock options and sold common shares on July 1, 2026. He exercised 6,214 option shares at $2.39 per share (cost $14,851). He sold a total of 9,836 shares in multiple open-market trades at a weighted-average price of $24.29, generating proceeds of $238,918. The sale transactions were executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: July 1, 2026. Report filed July 6, 2026 (appears to exceed the usual two-business-day Form 4 filing deadline).
• Option exercise: 6,214 shares exercised at $2.39 (total cash paid $14,851).
• Open-market sales: 9,836 shares sold at a weighted-average price of $24.29 for total proceeds of $238,918; reported trade prices ranged $23.68–$24.57 (footnote).
• Additional derivative entry: the filing also shows a derivative disposition of 6,214 shares at $0.00 (see filing/footnotes for settlement/withholding details).
• Plan/notes: Sales were made pursuant to a Rule 10b5-1 plan adopted Dec 3, 2025 (footnote F1). Several holdings are held in trusts for family members (multiple trust footnotes).
• Shares owned after the transactions: not specified in the excerpt provided — see the full Form 4 for post-transaction beneficial ownership totals.

Context

• This is an option exercise followed by immediate open-market sales (common "exercise and sell" activity). The 10b5-1 plan indicates the sales were pre-arranged, which is routine for insiders managing tax/liquidity needs and reduces the appearance of trading on material nonpublic information.
• The $0.00 derivative disposal line typically reflects shares surrendered or otherwise used in option settlement or withholding; consult the full filing for the precise mechanics.
• Sales are generally considered routine; purchases (not present here) are often treated as stronger bullish signals.